Literature DB >> 15019338

Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients.

Sureka Thiagalingam1, Maree Flaherty, Frank Billson, Kathryn North.   

Abstract

OBJECTIVE: To describe the natural history of optic pathway gliomas (OPGs) in patients with neurofibromatosis type 1 (NF1), and to evaluate the current recommended guidelines for monitoring and follow-up of OPGs in this population.
DESIGN: Retrospective case series. PARTICIPANTS: Patients with OPGs and NF1 seen in the neurofibromatosis clinic at the Children's Hospital at Westmead in Sydney, Australia.
METHODS: Patients with definite NF1 and confirmed OPGs were identified and their medical records searched to obtain data on demographics, details of the OPG diagnosis, and serial ophthalmic examination findings. Patients were stratified into groups according to age and mode of presentation. MAIN OUTCOME MEASURES: Visual acuity was recorded for each eye and grouped into mild (Snellen equivalent > or = 6/12), moderate (Snellen equivalent = 6/15-6/60), and severe (Snellen equivalent < 6/60) visual impairment at time of diagnosis, during follow-up, and at the most recent examination.
RESULTS: Data were collected on 54 patients, the majority of whom (78%) were seen from 1990 to 2002, with an average follow-up of 8.6 years. The mean age at the time of OPG diagnosis was 5.2 years, with 32 patients having symptoms or signs at the time of diagnosis. Seventeen patients were diagnosed after the age of 6 years (range, 7-15). Twenty-two patients had tumor progression within 1 year of diagnosis, and a further 6 patients showed progression after 1 year. Most patients' conditions were managed conservatively (68.5%). At follow-up, 17 patients (31.5%) had severe visual impairment (<6/60 Snellen equivalent) in their worse eye, and 16.7% had bilateral moderate/severe visual impairment.
CONCLUSIONS: Contrary to some previous reports, our results show that OPGs in patients with NF1 often present in older children and may progress some time after diagnosis. Given the potential for serious visual consequences, these findings indicate a need for regular ophthalmological monitoring of this population for a long duration.

Entities:  

Mesh:

Year:  2004        PMID: 15019338     DOI: 10.1016/j.ophtha.2003.06.008

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  41 in total

Review 1.  Pediatric low-grade gliomas.

Authors:  Angela J Sievert; Michael J Fisher
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

Review 2.  Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

Authors:  Peter M K de Blank; Michael J Fisher; Grant T Liu; David H Gutmann; Robert Listernick; Rosalie E Ferner; Robert A Avery
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

Review 3.  Neoplasms associated with germline and somatic NF1 gene mutations.

Authors:  Sachin Patil; Ronald S Chamberlain
Journal:  Oncologist       Date:  2012-01-12

4.  Investigation of retinal nerve fiber layer thickness and ganglion cell layer-inner plexiform layer thickness in patients with optic pathway gliomas.

Authors:  Mustafa Hepokur; Ahmet Murat Sarici
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-05-12       Impact factor: 3.117

Review 5.  Mosaic RASopathies.

Authors:  Christian Hafner; Leopold Groesser
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

6.  Assessment of chemotherapeutic response in children with proptosis due to optic nerve glioma.

Authors:  Roberto Jose Diaz; Suzanne Laughlin; Gary Nicolin; J Raymond Buncic; Eric Bouffet; Ute Bartels
Journal:  Childs Nerv Syst       Date:  2007-12-22       Impact factor: 1.475

7.  Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients.

Authors:  Fausto J Rodriguez; Arie Perry; David H Gutmann; Brian Patrick O'Neill; Jeffrey Leonard; Sandra Bryant; Caterina Giannini
Journal:  J Neuropathol Exp Neurol       Date:  2008-03       Impact factor: 3.685

Review 8.  Ophthalmological assessment of children with neurofibromatosis type 1.

Authors:  Catherine Cassiman; Eric Legius; Werner Spileers; Ingele Casteels
Journal:  Eur J Pediatr       Date:  2013-05-25       Impact factor: 3.183

9.  Orbital masses: CT and MRI of common vascular lesions, benign tumors, and malignancies.

Authors:  Sarah N Khan; Ali R Sepahdari
Journal:  Saudi J Ophthalmol       Date:  2012-10

Review 10.  Optic pathway gliomas: a review.

Authors:  Iris Fried; Uri Tabori; Tarik Tihan; Arun Reginald; Eric Bouffet
Journal:  CNS Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.